Prostate Cancer Treatment ~ Male BRCA / Breast Cancer
~ Genetics of Breast & Ovarian Cancer

Treatment for HBOC- or BRCA1/2 mutation-related prostate cancer

List was last updated on Dec 1, 2019 @ 8:02 am.


    • The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
    • van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, Bergman AM, van Oort IM, de Wit R, Voest EE, Steeghs N, Yamaguchi TN, Livingstone J, Boutros PC, Martens JWM, Sleijfer S, Cuppen E, Zwart W, van de Werken HJG, Mehra N, Lolkema MP.
    • Nat Commun. 2019 Nov 20;10(1):5251. doi: 10.1038/s41467-019-13084-7.
    • Hereditary prostate cancer - Primetime for genetic testing?
    • Heidegger I, Tsaur I, Borgmann H, Surcel C, Kretschmer A, Mathieu R, Visschere P, Valerio M, van den Bergh RCN, Ost P, Tilki D, Gandaglia G, Ploussard G; EAU-YAU Prostate Cancer Working Party.
    • Cancer Treat Rev. 2019 Nov 11;81:101927. doi: 10.1016/j.ctrv.2019.101927. [Epub ahead of print]
    • Review
    • Olaparib to Change Practice in mCRPC.
    • [No authors listed]
    • Cancer Discov. 2019 Oct 24. doi: 10.1158/2159-8290.CD-NB2019-126. [Epub ahead of print]
    • Research news
    • A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation.
    • Kosaka T, Hongo H, Aimono E, Matsumoto K, Hayashida T, Mikami S, Nishihara H, Oya M.
    • Pathol Int. 2019 Oct 20. doi: 10.1111/pin.12860. [Epub ahead of print]
    • Patients resistant against PSMA-targeting alpha-radiation therapy often harbor mutations in DNA-repair associated genes.
    • Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, Bruchertseifer F, Kippenberger M, Rathke H, Leichsenring J, Hohenfellner M, Morgenstern A, Haberkorn U, Duensing S, Stenzinger A.
    • J Nucl Med. 2019 Oct 10. pii: jnumed.119.234559. doi: 10.2967/jnumed.119.234559. [Epub ahead of print]
    • Towards precision oncology in advanced prostate cancer.
    • Ku SY, Gleave ME, Beltran H.
    • Nat Rev Urol. 2019 Oct 7. doi: 10.1038/s41585-019-0237-8. [Epub ahead of print]
    • Review
    • 'Landmark' Trial in Prostate Cancer With Mutations.
    • Davenport L.
    • Medscape Oncology. 2019 Oct 4.
    • Molecular insights into the germline for prostate cancer initiation, progression, and aggressiveness.
    • Pritchard CC.
    • Can J Urol. 2019 Oct;26(5S2):24-26.
    • The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
    • Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S.
    • Cancer Immunol Immunother. 2019 Sep 23. doi: 10.1007/s00262-019-02393-x. [Epub ahead of print]
    • Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review.
    • Swift SL, Lang SH, White H, Misso K, Kleijnen J, Quek RG.
    • Future Oncol. 2019 Sep 19. doi: 10.2217/fon-2019-0298. [Epub ahead of print]
    • Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
    • Petrovics G, Price DK, Lou H, Chen Y, Garland L, Bass S, Jones K, Kohaar I, Ali A, Ravindranath L, Young D, Cullen J, Dorsey TH, Sesterhenn IA, Brassell SA, Rosner IL, Ross D, Dahut W, Ambs S, Figg WD, Srivastava S, Dean M.
    • Prostate Cancer Prostatic Dis. 2019 Sep;22(3):406-410. doi: 10.1038/s41391-018-0114-1. Epub 2018 Dec 12.
    • Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
    • Adashek JJ, Jain RK, Zhang J.
    • Cells. 2019 Aug 9;8(8). pii: E860. doi: 10.3390/cells8080860.
    • Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    • Przybycinski J, Nalewajska M, Marchelek-Mysliwiec M, Dziedziejko V, Pawlik A.
    • Expert Opin Ther Targets. 2019 Aug 8. doi: 10.1080/14728222.2019.1654458. [Epub ahead of print]
    • Review
    • Myriad to Pursue mCRPC Approval for BRACAnalysis CDx
    • [No author given.]
    • Clinical Omics. 2019 Aug 7.
    • Myriad Genetics Seeking Additional FDA Approval for BRACAnalysis CDx.
    • [No author given]
    • GenomeWeb. 2019 Aug 7.
    • Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
    • Isaacsson Velho P, Qazi F, Hassan S, Carducci MA, Denmeade SR, Markowski MC, Thorek DL, DeWeese TL, Song DY, Tran PT, Eisenberger MA, Antonarakis ES.
    • Eur Urol. 2019 Aug;76(2):170-176. doi: 10.1016/j.eururo.2018.09.040. Epub 2018 Oct 4.
    • Bringing Prostate Cancer Germline Genetics into Clinical Practice.
    • Das S, Salami SS, Spratt DE, Kaffenberger SD, Jacobs MF, Morgan TM.
    • J Urol. 2019 Aug;202(2):223-230. doi: 10.1097/JU.0000000000000137. Epub 2019 Jul 8.
    • PARP Inhibitors in Prostate Cancer-The PreclinicalRationale and Current Clinical Development.
    • Virtanen V, Paunu K, Ahlskog JK, Varnai R, Sipeky C, Sundvall M.
    • Genes (Basel). 2019 Jul 26;10(8). pii: E565. doi: 10.3390/genes10080565.
    • Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.
    • Zhu J, Tucker M, Marin D, Gupta RT, Healy P, Humeniuk M, Jarvis C, Zhang T, McNamara M, George DJ, Wu Y, Lisi S, Armstrong AJ.
    • Urol Oncol. 2019 Jul 18. pii: S1078-1439(19)30244-3. doi: 10.1016/j.urolonc.2019.06.015. [Epub ahead of print]
    • Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.
    • Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS.
    • J Clin Invest. 2019 Jul 16;130. pii: 127613. doi: 10.1172/JCI127613.
    • Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
    • Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G, Yuan W, Dolling D, Welti JC, Neeb A, Sumanasuriya S, Rescigno , Bianchini D, Tunariu N, Carreira S, Sharp A, Oyen W, de Bono JS.
    • Eur Urol. 2019 Jul 13. pii: S0302-2838(19)30520-2. doi: 10.1016/j.eururo.2019.06.030. [Epub ahead of print]
    • 6-Thioguanine and Its Analogs Promote Apoptosis of Castration-Resistant Prostate Cancer Cells in a BRCA2-Dependent Manner.
    • Laera L, Guaragnella N, Giannattasio S, Moro L.
    • Cancers (Basel). 2019 Jul 5;11(7). pii: E945. doi: 10.3390/cancers11070945.
    • Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    • Criscuolo D, Morra F, Giannella R, Cerrato A, Celetti A.
    • Int J Mol Sci. 2019 Jun 25;20(12). pii: E3100. doi: 10.3390/ijms20123100.
    • A Multidisciplinary Approach to Individualized Patient Care - Prostate Cancer: The Emerging Role of Tumor and Germline Genetic Testing and the Treatment of Advanced Disease.
    • Srinivas S, Shah SA.
    • National Comprehensive Cancer Network. Continuing Education. 2019 Jun 24.
    • CME course
    • Resolution Bioscience, Janssen Partner to Develop CDx for Niraparib in Prostate Cancer.
    • [No author given]
    • GenomeWeb. 2019 Jun 19.
    • Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer.
    • Fujiwara M, Akamatsu S, Sumiyoshi T, Segawa T, Mizuno K, Yoshino T, Goto T, Sawada A, Saito R, Kobayashi T, Yamasaki T, Inoue T, Ogawa O.
    • Clin Genitourin Cancer. 2019 Jun 12. pii: S1558-7673(19)30179-X. doi: 10.1016/j.clgc.2019.04.017. [Epub ahead of print]
    • Screening, Active Surveillance, and Treatment of Localized Prostate Cancer Among Carriers of Germline BRCA Mutations.
    • Halstuch D, Ber Y, Margel D.
    • Eur Urol Focus. 2019 May 27. pii: S2405-4569(19)30146-4. doi: 10.1016/j.euf.2019.05.009. [Epub ahead of print]
    • Review
    • Novel poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, AZD2461, down-regulates VEGF and induces apoptosis in prostate cancer cells.
    • Sargazi S, Saravani R, Zavar Reza J, Zarei Jaliani H, Galavi H, Liliya Viacheslavovna M, Abtahi NA.
    • Iran Biomed J. 2019 May 18. [Epub ahead of print]
    • Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.002.
    • Liang J, Beckta JM, Bindra RS.
    • Eur Urol. 2019 May 9. pii: S0302-2838(19)30358-6. doi: 10.1016/j.eururo.2019.04.041. [Epub ahead of print]
    • Letter, Commentary

    Original research:

    Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.

    • Germline and Somatic Mutations in Prostate Cancer for the Clinician.
    • Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS.
    • J Natl Compr Canc Netw. 2019 May 1;17(5):515-521. doi: 10.6004/jnccn.2019.7307.
    • DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.
    • Warner EW, Yip SM, Chi KN, Wyatt AW.
    • BJU Int. 2019 May;123(5):769-776. doi: 10.1111/bju.14576. Epub 2018 Oct 26.
    • Review
    • Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    • Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K, Na R, Shi Z, Petkewicz J, Shah S, Fantus RJ, Novakovic K, Brendler CB, Zheng SL, Isaacs WB, Xu J.
    • Eur Urol. 2019 May;75(5):743-749. doi: 10.1016/j.eururo.2018.09.021. Epub 2018 Oct 8.

    Research news: DNA-Repair- Gene Mutations Linked to More Aggressive Prostate Cancer. (Medscape Oncology)

    • DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.
    • Lotan TL, Kaur HB, Alharbi AM, Pritchard CC, Epstein JI.
    • Histopathology. 2019 May;74(6):836-843. doi: 10.1111/his.13806. Epub 2019 Apr 1.
    • The influence of BRCA2 mutation on localized prostate cancer.
    • Taylor RA, Fraser M, Rebello RJ, Boutros PC, Murphy DG, Bristow RG, Risbridger GP.
    • Nat Rev Urol. 2019 May;16(5):281-290. doi: 10.1038/s41585-019-0164-8.
    • Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
    • Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan C, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN; PCCTC Germline Genetics Working Group.
    • Clin Genitourin Cancer. 2019 Apr 18. pii: S1558-7673(19)30139-9. doi: 10.1016/j.clgc.2019.04.013. [Epub ahead of print]
    • Myriad Genetics Expands CDx Collaboration with AstraZeneca, Merck & Co.
    • [No author given.]
    • Clinical Omics. 2019 Apr 4.
    • Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance.
    • Horak P, Weischenfeldt J, von Amsberg G, Beyer B, Schütte A, Uhrig S, Gieldon L, Klink B, Feuerbach L, Hübschmann D, Kreutzfeldt S, Heining C, Maier S, Hutter B, Penzel R, Schlesner M, Eils R, Sauter G, Stenzinger A, Brors B, Schröck E, Glimm H, Fröhling S, Schlomm T.
    • Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003657. doi: 10.1101/mcs.a003657. Print 2019 Apr.
    • A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
    • Köcher S, Beyer B, Lange T, Nordquist L, Volquardsen J, Burdak-Rothkamm S, Schlomm T, Petersen C, Rothkamm K, Mansour WY.
    • Int J Cancer. 2019 Apr 1;144(7):1685-1696. doi: 10.1002/ijc.32018. Epub 2019 Jan 5.
    • Evolving Role of Genomics in Genitourinary Neoplasms.
    • Devitt ME, Dreicer R.
    • Acta Med Acad. 2019 Apr;48(1):68-77. doi: 10.5644/ama2006-124.243.
    • Niraparib Shrinks BRCA-Mutated Prostate Tumors.
    • [No authors listed]
    • Cancer Discov. 2019 Apr;9(4):OF7. doi: 10.1158/2159-8290.CD-NB2019-030. Epub 2019 Mar 1.
    • Research News
    • BRCAness in prostate cancer.
    • Bednarz-Knoll N, Eltze E, Semjonow A, Brandt B.
    • Oncotarget. 2019 Mar 29;10(25):2421-2422. doi: 10.18632/oncotarget.26818. eCollection 2019 Mar 29.
    • Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
    • Athie A, Arce-Gallego S, Gonzalez M, Morales-Barrera R, Suarez C, Casals Galobart T, Hernandez Viedma G, Carles J, Mateo J.
    • Curr Oncol Rep. 2019 Mar 27;21(5):42. doi: 10.1007/s11912-019-0790-6.
    • Review
    • The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
    • Oh M, Alkhushaym N, Fallatah S, Althaghfi A, Aljadeed R, Alsowaida Y, Jeter J, Martin JR, Babiker HM, McBride A, Abraham I.
    • Prostate. 2019 Mar 22. doi: 10.1002/pros.23795. [Epub ahead of print]
    • Meta-Analysis
    • BRCA2 and Other DDR Genes in Prostate Cancer.
    • Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E.
    • Cancers (Basel). 2019 Mar 12;11(3). pii: E352. doi: 10.3390/cancers11030352.
    • Targeting the lysosome by an aminomethylated Riccardin D triggers DNA damage through cathepsin B-mediated degradation of BRCA1.
    • Wang Y, Niu H, Hu Z, Zhu M, Wang L, Han L, Qian L, Tian K, Yuan H, Lou H.
    • J Cell Mol Med. 2019 Mar;23(3):1798-1812. doi: 10.1111/jcmm.14077. Epub 2018 Dec 18.
    • Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response.
    • Zhang W, van Weerden WM, de Ridder CMA, Erkens-Schulze S, Schönfeld E, Meijer TG, Kanaar R, van Gent DC, Nonnekens J.
    • Prostate. 2019 Mar;79(4):390-402. doi: 10.1002/pros.23745. Epub 2018 Dec 5.
    • Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage.
    • Marshall CH, Fu W, Wang H, Baras AS, Lotan TL, Antonarakis ES.
    • Prostate Cancer Prostatic Dis. 2019 Mar;22(1):59-65. doi: 10.1038/s41391-018-0086-1. Epub 2018 Aug 31.
    • Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    • Marshall CH, Sokolova AO, McNatty AL, Cheng HH, Eisenberger MA, Bryce AH, Schweizer MT, Antonarakis ES.
    • Eur Urol. 2019 Feb 20. pii: S0302-2838(19)30110-1. doi: 10.1016/j.eururo.2019.02.002. [Epub ahead of print]
    • PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
    • Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, Gonzalez-Billalabeitia E, Cendón Y, García-Carbonero I, Borrega P, Mendez Vidal MJ, Montesa A, Nombela P, Fernández-Parra E, Gonzalez Del Alba A, Villa-Guzmán JC, Ibáñez K, Rodriguez-Vida A, Magraner-Pardo L, Perez-Valderrama B, Vallespín E, Gallardo E, Vazquez S, Pritchard CC, Lapunzina P, Olmos D.
    • J Clin Oncol. 2019 Feb 20;37(6):490-503. doi: 10.1200/JCO.18.00358. Epub 2019 Jan 9.
    • Metastatic Prostate Cancer: Effects of Genetic Testing on Care.
    • Connors LM.
    • Clin J Oncol Nurs. 2019 Feb 1;23(1):32-35. doi: 10.1188/19.CJON.32-35.
    • Review
    • Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.
    • Omari A, Nastały P, Stoupiec S, Bałabas A, Dąbrowska M, Bielińska B, Huss S, Pantel K, Semjonow A, Eltze E, Brandt B, Bednarz-Knoll N.
    • Int J Cancer. 2019 Feb 1;144(3):607-614. doi: 10.1002/ijc.31905. Epub 2018 Oct 22.
    • Tumor Lysis Syndrome After Platinum-based Chemotherapy in Castration-resistant Prostate Cancer With a BRCA2 Mutation: A Case Report.
    • Gongora ABL, Canedo FSNA, de Melo ALA, Bezerra ROF, Asprino PF, Camargo AA, Bastos DA.
    • Clin Genitourin Cancer. 2019 Feb;17(1):e61-e64. doi: 10.1016/j.clgc.2018.09.001. Epub 2018 Sep 7.
    • The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.
    • Pilarski R.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):79-86. doi: 10.1200/EDBK_238977.
    • Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
    • Petrovics G, Price DK, Lou H, Chen Y, Garland L, Bass S, Jones K, Kohaar I, Ali A, Ravindranath L, Young D, Cullen J, Dorsey TH, Sesterhenn IA, Brassell SA, Rosner IL, Ross D, Dahut W, Ambs S, Figg WD, Srivastava S, Dean M.
    • Prostate Cancer Prostatic Dis. 2018 Dec 12. doi: 10.1038/s41391-018-0114-1. [Epub ahead of print]
    • Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.
    • Fenerty KE, Padget M, Wolfson B, Gameiro SR, Su Z, Lee JH, Rabizadeh S, Soon-Shiong P, Hodge JW.
    • J Immunother Cancer. 2018 Nov 29;6(1):133. doi: 10.1186/s40425-018-0445-4.
    • Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
    • Ma Y, He L, Huang Q, Zheng S, Zhang Z, Li H, Liu S.
    • BMC Med Genet. 2018 Oct 17;19(1):185. doi: 10.1186/s12881-018-0703-9.
    • A Devastatingly "Minor" Relationship Between Male Breast Cancer and Prostate Cancer.
    • Kolli S, Asarian A, Genato R, Xiao P.
    • Cureus. 2018 Oct 17;10(10):e3463. doi: 10.7759/cureus.3463.
    • [DNA damage repair: An emerging strategy in metastatic prostate cancer].
    • Loriot Y, Meynard G, Klajer E, Bolognini C, Gassian N, Thiery-Vuillemin A.
    • Bull Cancer. 2018 Oct;105(10):944-954. doi: 10.1016/j.bulcan.2018.05.017. Epub 2018 Sep 29.
    • Review, [Article in French]
    • Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?
    • Caffo O, Veccia A, Kinspergher S, Rizzo M, Maines F.
    • Front Cell Dev Biol. 2018 Sep 5;6:71. doi: 10.3389/fcell.2018.00071. eCollection 2018.
    • Prostate Cancer Germline Variations and Implications for Screening and Treatment.
    • Dias A, Kote-Jarai Z, Mikropoulos C, Eeles R.
    • Cold Spring Harb Perspect Med. 2018 Sep 4;8(9). pii: a030379. doi: 10.1101/cshperspect.a030379.
    • Review
    • Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?
    • Di Nunno V, Santoni M, Massari F.
    • Lancet Oncol. 2018 Sep;19(9):e437-e438. doi: 10.1016/S1470-2045(18)30458-3.

    Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.

    Letter, Reply: Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? – Authors' reply (Lancet Oncology)

    • A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy.
    • Liu Q, Tong D, Liu G, Yi Y, Xu J, Yang X, Wang L, Zhang J, Ye J, Zhang Y, Yuan G, Wang P, Chen R, Guan Y, Yi X, Zhang D, Jiang J.
    • Cancer Biol Ther. 2018 Aug 3;19(8):669-675. doi: 10.1080/15384047.2018.1451278. Epub 2018 Apr 19.
    • Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
    • Frank S, Nelson P, Vasioukhin V.
    • F1000Res. 2018 Aug 2;7. pii: F1000 Faculty Rev-1173. doi: 10.12688/f1000research.14499.1. eCollection 2018.
    • BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy.
    • Ahmadzadehfar H, Gaertner F, Lossin PS1, Schwarz B, Essler M.
    • Clin Nucl Med. 2018 Aug;43(8):609-610. doi: 10.1097/RLU.0000000000002141.
    • Case report
    • Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    • Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, Silberstein JL, Piana D, Lai Z, Chen Y, Isaacs WB, Luo J.
    • Eur Urol. 2018 Aug;74(2):218-225. doi: 10.1016/j.eururo.2018.01.035. Epub 2018 Feb 10.
    • DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
    • Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ.
    • J Natl Compr Canc Netw. 2018 Aug;16(8):933-937. doi: 10.6004/jnccn.2018.7020.
    • Molecular correlates of intermediate- and high-risk localized prostate cancer.
    • Ye H, Sowalsky AG.
    • Urol Oncol. 2018 Aug;36(8):368-374. doi: 10.1016/j.urolonc.2017.12.022. Epub 2018 Mar 2.
    • Review
    • The resounding effect of DNA repair deficiency in prostate cancer.
    • Cheng HH.
    • Urol Oncol. 2018 Aug;36(8):385-388. doi: 10.1016/j.urolonc.2018.02.014. Epub 2018 Mar 17.
    • Review
    • DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC).
    • Rathi N, Anderson N, Greenberg S, Vagher J, Agarwal N, Hahn AW.
    • World J Oncol. 2018 Aug;9(4):119-122. doi: 10.14740/wjon1144w. Epub 2018 Sep 6.
    • PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
    • Yin L, Liu Y, Peng Y, Peng Y, Yu X, Gao Y, Yuan B, Zhu Q, Cao T, He L, Gong Z, Sun L, Fan X, Li X.
    • J Exp Clin Cancer Res. 2018 Jul 16;37(1):153. doi: 10.1186/s13046-018-0810-7.
    • Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer.
    • Chanez B, Chaffanet M, Adélaide J, Thomassin J, Garnier S, Carbuccia N, Guille A, Charrier N, Brenot-Rossi I, Walz J, Pignot G, Pakradouni J, Gonçalvès A, Eisinger F, Bertucci F, Birnbaum D, Gravis G.
    • JCO Precis Oncol. 2018 Jul 10;2018. doi: 10.1200/PO.18.00083. Epub 2018 Jul 10.
    • Case report
    • Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.
    • Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES.
    • Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564. eCollection 2018 Jun 19.
    • Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise.
    • Sumanasuriya S, De Bono J.
    • Cold Spring Harb Perspect Med. 2018 Jun 1;8(6). pii: a030635. doi: 10.1101/cshperspect.a030635.
    • Molecular Subtypes of Prostate Cancer.
    • Arora K, Barbieri CE.
    • Curr Oncol Rep. 2018 Jun 1;20(8):58. doi: 10.1007/s11912-018-0707-9.
    • Review
    • Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer.
    • Cheng H, Powers J, Schaffer K, Sartor O.
    • Am Soc Clin Oncol Educ Book. 2018 May 23;(38):372-381. doi: 10.1200/EDBK_205441.
    • Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.
    • Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, Kolinsky M, Balasopoulou A, Bertan C, Nanus DM, Tagawa ST, Thorne H, Montgomery B, Carreira S, Sandhu S, Rubin MA, Nelson PS, de Bono JS.
    • Eur Urol. 2018 May;73(5):687-693. doi: 10.1016/j.eururo.2018.01.010. Epub 2018 Feb 8.
    • Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
    • Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN.
    • Cancer Discov. 2018 Apr;8(4):444-457. doi: 10.1158/2159-8290.CD-17-0937. Epub 2018 Jan 24.

    Research news:

    Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test.

    • DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223.
    • Ramos JD, Mostaghel EA, Pritchard CC, Yu EY.
    • Clin Genitourin Cancer. 2018 Apr;16(2):106-110. doi: 10.1016/j.clgc.2017.11.009. Epub 2017 Dec 6.
    • PARP1-siRNA suppresses human prostate cancer cell growth and progression.
    • Lai Y, Kong Z, Zeng T, Xu S, Duan X, Li S, Cai C, Zhao Z, Wu W.
    • Oncol Rep. 2018 Apr;39(4):1901-1909. doi: 10.3892/or.2018.6238. Epub 2018 Jan 26.
    • Germline BRCA mutation in male carriers-ripe for precision oncology?
    • Leão RRN, Price AJ, James Hamilton R.
    • Prostate Cancer Prostatic Dis. 2018 Apr;21(1):48-56. doi: 10.1038/s41391-017-0018-5. Epub 2017 Dec 14.
    • Review
    • Men with a susceptibility to prostate cancer and the role of genetic based screening.
    • Eeles R, Ni Raghallaigh H.
    • Transl Androl Urol. 2018 Feb;7(1):61-69. doi: 10.21037/tau.2017.12.30.
    • BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy.
    • Conteduca V, Sigouros M, Sboner A, Pritchard CC, Beltran H.
    • JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00115. Epub 2018 Jun 29.
    • Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.
    • Carneiro BA, Collier KA, Nagy RJ, Pamarthy S, Sagar V, Fairclough S, Odegaard J, Lanman RB, Costa R, Taxter T, Kuzel TM, Fan A, Chae YK, Cristofanilli M, Hussain MH, Abdulkadir SA, Giles FJ.
    • JCO Precis Oncol. 2018;2. doi: 10.1200/PO.17.00176. Epub 2018 Feb 14.
    • Olaparib.
    • Bochum S, Berger S, Martens UM.
    • Recent Results Cancer Res. 2018;211:217-233. doi: 10.1007/978-3-319-91442-8_15.
    • Review
    • [Prostate cancer and DNA repair genes].
    • Penel N.
    • Bull Cancer. 2017 Nov;104(11):958-961. doi: 10.1016/j.bulcan.2017.07.005. Epub 2017 Oct 9.
    • Letter, [Article in French]
    • A Novel Use for Olaparib for Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    • Martin GA, Chen AH, Parikh K.
    • Pharmacotherapy. 2017 Nov;37(11):1406-1414. doi: 10.1002/phar.2027.
    • Review
    • Combining Enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness.
    • Thompson TC, Li L, Broom BM.
    • Oncotarget. 2017 Oct 25. doi: 10.18632/oncotarget.22074. [Epub ahead of print]
    • Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    • Özdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK.
    • Eur Urol Focus. 2017 Oct 19. pii: S2405-4569(17)30238-9. doi: 10.1016/j.euf.2017.10.001. [Epub ahead of print]
    • Review
    • The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
    • Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT, Szállási Z, Oh WK, Kantoff PW, Garber JE, Schrag D, Kibel AS, Freedman ML.
    • Cancer. 2017 Sep 15;123(18):3532-3539. doi: 10.1002/cncr.30808. Epub 2017 Jun 13.

    Editorial:

    Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-Mutated prostate cancers.

    • Analysis of Circulating Cell-free DNA Identifies Multi-clonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
    • Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard CC, Thomas GV, Tomlins SA, Knudsen KE, Lord CJ, Ryan CJ, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY.
    • Cancer Discov. 2017 Sep;7(9):999-1005. doi: 10.1158/2159-8290.CD-17-0146. Epub 2017 Apr 27.

    Review:

    Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.

    • Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
    • Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S, Fowler G, Ebbs B, Flohr P, Seed G, Nava Rodrigues D, Boysen G, Bertan C, Atkin M, Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S, Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS.
    • Cancer Discov. 2017 Sep;7(9):1006-1017. doi: 10.1158/2159-8290.CD-17-0261. Epub 2017 Apr 27.

    Research news:

    New blood test could extend prostate cancer survival.

    Review:

    Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.

    Press: New three-in-one blood test opens door to precision medicine for prostate cancer. (MedicalXpress)

    • Commentary on "Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer". Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Eur Urol. Jun 2016;69(6):992-5.
    • Freedland S, Aronson W.
    • Urol Oncol. 2017 Aug;35(8):536. doi: 10.1016/j.urolonc.2017.05.011. Epub 2017 Jun 13.
    • Commentary

    Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.

    • Mutations in BRCA2 and taxane resistance in prostate cancer.
    • Nientiedt C, Heller M, Endris V, Volckmar AL, Zschäbitz S, Tapia-Laliena MA, Duensing A, Jäger D, Schirmacher P, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.
    • Sci Rep. 2017 Jul 4;7(1):4574. doi: 10.1038/s41598-017-04897-x.
    • Relevance of DNA damage repair in the management of prostate cancer.
    • Banks P, Xu W, Murphy D, James P, Sandhu S.
    • Curr Probl Cancer. 2017 Jul - Aug;41(4):287-301. doi: 10.1016/j.currproblcancer.2017.06.001. Epub 2017 Jun 27.
    • Review
    • Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
    • Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW.
    • Eur Urol. 2017 Jul;72(1):34-42. doi: 10.1016/j.eururo.2017.02.023. Epub 2017 Mar 1.
    • Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.
    • Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, Arcila ME, Zehir A, Syed A, Gao J, Chakravarty D, Vargas HA, Robson ME, Joseph V, Offit K, Donoghue MTA, Abeshouse AA, Kundra R, Heins ZJ, Penson AV, Harris C, Taylor BS, Ladanyi M, Mandelker D, Zhang L, Reuter VE, Kantoff PW, Solit DB, Berger MF, Sawyers CL, Schultz N, Scher HI.
    • JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00029. Epub 2017 May 31.
    • Intraductal Carcinoma of the Prostate: A Risk for Rapid Recurrence.
    • Dinerman BF, Bernstein AN, Khani F, Hu JC.
    • Urology. 2017 Jul;105:e1-e2. doi: 10.1016/j.urology.2017.03.030. Epub 2017 Mar 28.
    • Review
    • BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer.
    • Cui M, Gao XS, Gu X, Guo W, Li X, Ma M, Qin S, Qi X, Xie M, Peng C, Bai Y.
    • Oncotarget. 2017 Jun 20;8(25):40222-40232. doi: 10.18632/oncotarget.16712.
    • PARP Inhibitors in Prostate Cancer.
    • Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK.
    • Curr Treat Options Oncol. 2017 Jun;18(6):37. doi: 10.1007/s11864-017-0480-2.
    • Review
    • Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
    • Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC.
    • Sci Signal. 2017 May 23;10(480). pii: eaam7479. doi: 10.1126/scisignal.aam7479.

    Research news: Expanding the use of PARP inhibitors. (Nature Reviews Cancer)

    • 5 Big Questions (and Answers) on Inherited Prostate Cancer Testing.
    • Nick Mulcahy
    • Medscape. Coverage from the American Urological Association (AUA) 2017 Annual Meeting. 2017 May 18.
    • Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.
    • Romero-Laorden N, Piñeiro-Yañez E, Gutierrez-Pecharroman A, Pacheco MI, Calvo E, Al-Shahrour F, Castro E, Olmos D1.
    • Ann Oncol. 2017 May 1;28(5):1158-1159. doi: 10.1093/annonc/mdx067.
    • Letter, Case report
    • Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer.
    • Purshouse K, Schuh A, Fairfax BP, Knight S, Antoniou P, Dreau H, Popitsch N, Gatter K, Roberts I, Browning L, Traill Z, Kerr D, Verrill C, Tuthill M, Taylor JC, Protheroe A.
    • Cold Spring Harb Mol Case Stud. 2017 May;3(3):a001362. doi: 10.1101/mcs.a001362.
    • EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    • Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RC, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P.
    • Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.
    • Conference Report, Review
    • Changing face of metastatic prostate cancer: the law of diminishing returns holds true.
    • Vaishampayan UN.
    • Curr Opin Oncol. 2017 Mar 18. doi: 10.1097/CCO.0000000000000370. [Epub ahead of print]
    • Review
    • Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
    • De Felice F, Tombolini V, Marampon F, Musella A, Marchetti C.
    • Drug Des Devel Ther. 2017 Mar 1;11:547-552. doi: 10.2147/DDDT.S110264. eCollection 2017.
    • Prostate cancer heterogeneity: Discovering novel molecular targets for therapy.
    • Ciccarese C, Massari F, Iacovelli R, Fiorentino M, Montironi R, Di Nunno V, Giunchi F, Brunelli M, Tortora G.
    • Cancer Treat Rev. 2017 Mar;54:68-73. doi: 10.1016/j.ctrv.2017.02.001. Epub 2017 Feb 11.
    • Review
    • DNA Repair in Prostate Cancer: Biology and Clinical Implications.
    • Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS.
    • Eur Urol. 2017 Mar;71(3):417-425. doi: 10.1016/j.eururo.2016.08.037. Epub 2016 Aug 31.
    • Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer.
    • Teply BA, Kachhap S, Eisenberger MA, Denmeade SR.
    • Eur Urol. 2017 Mar;71(3):499. doi: 10.1016/j.eururo.2016.09.020. Epub 2016 Sep 29.
    • Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
    • Li J, Wang R, Kong Y, Broman MM, Carlock C, Chen L, Li Z, Farah E, Ratliff TL, Liu X.
    • Mol Cancer Ther. 2017 Mar;16(3):469-479. doi: 10.1158/1535-7163.MCT-16-0361. Epub 2017 Jan 9.
    • Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation.
    • Steinberger AE, Cotogno P, Ledet EM, Lewis B, Sartor O.
    • Clin Genitourin Cancer. 2017 Feb;15(1):e69-e71. doi: 10.1016/j.clgc.2016.09.001. Epub 2016 Sep 17.
    • Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
    • Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG.
    • Nat Commun. 2017 Jan 9;8:13671. doi: 10.1038/ncomms13671.

    Research News:

    Prostate cancer: Genomic drivers of BRCA2-mutant tumours.

    • PARP inhibition in BRCA2-mutated prostate cancer.
    • Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.
    • Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445.
    • PARP inhibitors and stratified treatment of prostate cancer.
    • Lavery A, Gilson C, Chowdhury S.
    • Expert Rev Anticancer Ther. 2016 Dec;16(12):1213-1215. Epub 2016 Oct 17.
    • Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
    • Buonerba C, Di Lorenzo G, Sonpavde G.
    • Expert Rev Mol Diagn. 2016 Oct;16(10):1113-1120. Epub 2016 Sep 28.
    • Review
    • Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer.
    • Modena A, Iacovelli R, Scarpa A, Brunelli M, Ciccarese C, Fantinel E, Bimbatti D, Massari F, Martignoni G, Tortora G.
    • Target Oncol. 2016 Oct;11(5):569-577.
    • Review
    • Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
    • Castro E, Mateo J, Olmos D, de Bono JS.
    • Cancer J. 2016 Sep/Oct;22(5):353-356.
    • Review
    • Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers.
    • Gleicher S, Kauffman EC, Kotula L, Bratslavsky G, Vourganti S.
    • Prostate. 2016 Sep;76(13):1135-45. doi: 10.1002/pros.23204. Epub 2016 May 26.
    • Meta-Analysis, Review
    • DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    • Dhawan M, Ryan CJ, Ashworth A.
    • Oncologist. 2016 Aug;21(8):940-5. doi: 10.1634/theoncologist.2016-0135. Epub 2016 Jun 17.
    • Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.
    • Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B.
    • Eur Urol. 2016 Jun;69(6):992-5. doi: 10.1016/j.eururo.2015.11.022. Epub 2015 Dec 24.

    Commentary:

    Commentary on "Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer". Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Eur Urol. Jun 2016;69(6):992-5.

    • The Clinical Impact of BRCA2 Loss in Prostate Cancer.
    • Bryant HE.
    • Eur Urol. 2016 Jun;69(6):996-7. doi: 10.1016/j.eururo.2015.12.009. Epub 2015 Dec 18.
    • Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.
    • Decker B, Karyadi DM, Davis BW, Karlins E, Tillmans LS, Stanford JL, Thibodeau SN, Ostrander EA.
    • Am J Hum Genet. 2016 May 5;98(5):818-829. doi: 10.1016/j.ajhg.2016.03.003. Epub 2016 Apr 14.
    • PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations.
    • Helleday T.
    • Ann Oncol. 2016 May;27(5):755-7. doi: 10.1093/annonc/mdw048. Epub 2016 Feb 9.
    • Editorial
    • Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
    • Palmbos PL, Hussain MH.
    • Oncology (Williston Park). 2016 May;30(5). pii: 217036.

    Comment:

    PARP Inhibition in Prostate Cancer: A Promising Approach.

    • Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer.
    • Chedgy EC, Annala M, Beja K, Warner EW, Gleave ME, Chi KN, Wyatt AW.
    • Clin Genitourin Cancer. 2016 Apr;14(2):e233-6. doi: 10.1016/j.clgc.2015.12.023. Epub 2015 Dec 24.
    • Plumbagin, a naphthaquinone derivative induces apoptosis in BRCA 1/2 defective castrate resistant prostate cancer cells as well as prostate cancer stem-like cells.
    • R S R, K H S, Somasundaram V, S SK, Nadhan R, Nair RS, Srinivas P.
    • Pharmacol Res. 2016 Mar;105:134-45. doi: 10.1016/j.phrs.2016.01.012. Epub 2016 Jan 22.
    • Caring for Patients With Prostate Cancer Who Are BRCA Positive.
    • Hartzfeld D, Berse B, Lowrance W, Dash A, Brawer M, Lawrence J, Meyer L, Lynch J.
    • Fed Pract. 2016 Feb;33(Suppl 1):46S-51S.
    • Prostate Cancer Gene Alterations Support Potential Role of PARP inhibitors.
    • Bryant Furlow.
    • OncoTherapy Network. 2016 Jan 15.
    • High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
    • Castro E, Jugurnauth-Little S, Karlsson Q, Al-Shahrour F, Piñeiro-Yañez E, Van de Poll F, Leongamornlert D, Dadaev T, Govindasami K, Guy M, Eeles R, Kote-Jarai Z; UKGPCS, EMBRACE and IMPACT studies.
    • Ann Oncol. 2015 Nov;26(11):2293-300. doi: 10.1093/annonc/mdv356. Epub 2015 Sep 7.
    • Molecular landscape of prostate cancer: Implications for current clinical trials.
    • Khemlina G, Ikeda S, Kurzrock R.
    • Cancer Treat Rev. 2015 Nov;41(9):761-6. doi: 10.1016/j.ctrv.2015.07.001. Epub 2015 Jul 9.
    • DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
    • Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS.
    • N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.

    Third of men with treatment resistant prostate cancer respond to drug that targets gene defect, study finds

    Molecular stratification and repair defects: revealing hidden treasures.

    • Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma.
    • Ploquin A, Baldini C, Vuagnat P, Makhloufi S, Desauw C, Hebbar M.
    • Case Rep Oncol. 2015 Oct 22;8(3):447-450. doi: 10.1159/000441414.
    • To BRCA or Not to PALB.
    • McNamara MG, Lamarca A, Hubner RA, Valle JW.
    • J Clin Oncol. 2015 Aug 10;33(23):2581-2. doi: 10.1200/JCO.2014.60.0585. Epub 2015 Jun 29.

    Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

    Letter:

    Reply to M.G. McNamara et al and M.S. Copur et al.

    • Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.
    • Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T, Govindasami K, Guy M, Ellis S, Frost D, Bancroft E, Cole T, Tischkowitz M, Kennedy MJ, Eason J, Brewer C, Evans DG, Davidson R, Eccles D, Porteous ME, Douglas F, Adlard J, Donaldson A, Antoniou AC, Kote-Jarai Z, Easton DF, Olmos D, Eeles R.
    • Eur Urol. 2015 Aug;68(2):186-93. doi: 10.1016/j.eururo.2014.10.022. Epub 2014 Nov 6.

    Comment / Editorial:

    Clinical Management of Prostate Cancer in Men with BRCA Mutations.

    • Clinical Management of Prostate Cancer in Men with BRCA Mutations.
    • Bratt O, Loman N.
    • Eur Urol. 2015 Aug;68(2):194-5. doi: 10.1016/j.eururo.2014.11.005. Epub 2014 Nov 15.
    • Editorial / Commentary

    Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.

    • Sequences and combinations of multifaceted therapy in advanced prostate cancer.
    • Vaishampayan UN.
    • Curr Opin Oncol. 2015 May;27(3):201-8. doi: 10.1097/CCO.0000000000000187.
    • Role of PARP-1 in prostate cancer.
    • Deshmukh D, Qiu Y.
    • Am J Clin Exp Urol. 2015 Apr 25;3(1):1-12. eCollection 2015.
    • Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    • Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM.
    • J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.

    Comment / Letter:

    Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?

    Letter:

    To BRCA or Not to PALB.

    Letter:

    Reply to M.G. McNamara et al and M.S. Copur et al.

    Comment / Editorial:

    The Long and Winding Road.

    Press: Olaparib Trial Offers a Look at Precision Medicine's Future. (Medscape Oncology)

    • Olaparib effective in four advanced cancers.
    • [No authors listed]
    • Cancer Discov. 2015 Jan;5(1):OF3. doi: 10.1158/2159-8290.CD-NB2014-176. Epub 2014 Dec 9.
    • PCAT-1, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer.
    • Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY.
    • Cancer Res. 2014 Mar 15;74(6):1651-60. doi: 10.1158/0008-5472.CAN-13-3159. Epub 2014 Jan 28.
    • Clinical features and management of BRCA1 and BRCA2-associated prostate cancer.
    • Alanee SR, Glogowski EA, Schrader KA, Eastham JA, Offit K.
    • Front Biosci (Elite Ed). 2014 Jan 1;6:15-30.
    • PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
    • Lee JM, Ledermann JA, Kohn EC.
    • Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12.
    • The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    • Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM.
    • Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28.

    Commentary:

    PARP inhibitors: pitfalls and promises.

    • Olaparib shows promise in multiple tumor types.
    • [No authors listed]
    • Cancer Discov. 2013 Jul;3(7):OF5. doi: 10.1158/2159-8290.CD-NB2013-082. Epub 2013 Jun 6.
    • Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer.
    • Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K, Guy M, Sawyer E, Wilkinson R, Ardern-Jones A, Ellis S, Frost D, Peock S, Evans DG, Tischkowitz M, Cole T, Davidson R, Eccles D, Brewer C, Douglas F, Porteous ME, Donaldson A, Dorkins H, Izatt L, Cook J, Hodgson S, Kennedy MJ, Side LE, Eason J, Murray A, Antoniou AC, Easton DF, Kote-Jarai Z, Eeles R.
    • J Clin Oncol. 2013 May 10;31(14):1748-57. doi: 10.1200/JCO.2012.43.1882. Epub 2013 Apr 8.

    Comment:

    Re: Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

    Research news:

    Patients with prostate cancer and BRCA2 mutations need urgent treatment.

    Press: Gene linked to more aggressive prostate cancer. (PHG Foundation)

    Press: First genetic factor in prostate cancer prognosis identified. (EurekAlert!)

    • Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.
    • Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J.
    • Ann Oncol. 2013 May;24(5):1416-8. doi: 10.1093/annonc/mdt074. Epub 2013 Mar 22.
    • Familial prostate cancer: the damage done and lessons learnt.
    • Taherian N, Hamel N, Bégin LR, Bismar TA, Goldgar DE, Feng BJ, Foulkes WD.
    • Nat Rev Urol. 2013 Feb;10(2):116-22. doi: 10.1038/nrurol.2012.257. Epub 2013 Jan 15.
    • High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
    • Willems-Jones A, Kavanagh L, Clouston D, Bolton D; kConFab Investigators, Fox S, Thorne H.
    • BJU Int. 2012 Dec;110(11 Pt C):E1181-6. doi: 10.1111/j.1464-410X.2012.11519.x. Epub 2012 Oct 4.
    • Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    • Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.
    • Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

    Comment:

    Addicted to PAR? A closer look at PARP inhibitor sensitivity.

    Comment:

    Predicting PARP inhibitor sensitivity and resistance.

    • The role of BRCA1 and BRCA2 in prostate cancer.
    • Castro E, Eeles R.
    • Asian J Androl. 2012 May;14(3):409-14. doi: 10.1038/aja.2011.150. Epub 2012 Apr 23.
    • Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.
    • Gallagher DJ, Cronin AM, Milowsky MI, Morris MJ, Bhatia J, Scardino PT, Eastham JA, Offit K, Robson ME.
    • BJU Int. 2012 Mar;109(5):713-9. doi: 10.1111/j.1464-410X.2011.10292.x. Epub 2011 Jul 14.